{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T23:24:11Z","timestamp":1793748251871,"version":"4.6.1"},"reference-count":66,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,28]],"date-time":"2025-01-28T00:00:00Z","timestamp":1738022400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology Congenital Heart Disease"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.ijcchd.2025.100571","type":"journal-article","created":{"date-parts":[[2025,1,30]],"date-time":"2025-01-30T23:01:26Z","timestamp":1738278086000},"page":"100571","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["New therapies in pulmonary arterial hypertension: Recent insights"],"prefix":"10.1016","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-3437-3004","authenticated-orcid":false,"given":"Giulia","family":"Guglielmi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Konstantinos","family":"Dimopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. John","family":"Wort","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijcchd.2025.100571_bib1","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01887-2018","article-title":"Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives","volume":"53","author":"Humbert","year":"2019","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.ijcchd.2025.100571_bib2","doi-asserted-by":"crossref","first-page":"343","DOI":"10.7326\/0003-4819-115-5-343","article-title":"Survival in patients with primary pulmonary hypertension. Results from a national prospective registry","volume":"115","author":"D'Alonzo","year":"1991","journal-title":"Ann Intern Med"},{"issue":"4","key":"10.1016\/j.ijcchd.2025.100571_bib3","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.12137","article-title":"The evolution of survival of pulmonary arterial hypertension over 15 years","volume":"12","author":"Hendriks","year":"2022","journal-title":"Pulm Circ"},{"issue":"6","key":"10.1016\/j.ijcchd.2025.100571_bib4","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02419-2021","article-title":"External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry","volume":"59","author":"Boucly","year":"2022","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.ijcchd.2025.100571_bib5","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02341-2020","article-title":"Targeting transforming growth factor-\u03b2 receptors in pulmonary hypertension","volume":"57","author":"Guignabert","year":"2021","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.ijcchd.2025.100571_bib6","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.3390\/ijms19092585","article-title":"TGF-\u0392 and BMPR2 signaling in PAH: two Black sheep in One family","volume":"19","author":"Rol","year":"2018","journal-title":"Int J Mol Sci"},{"issue":"1, Supplement","key":"10.1016\/j.ijcchd.2025.100571_bib7","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1016\/j.jacc.2009.04.015","article-title":"Genetics and genomics of pulmonary arterial hypertension","volume":"54","author":"Machado","year":"2009","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.ijcchd.2025.100571_bib8","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/humu.9251","article-title":"BMPR2 mutations found in Japanese patients with familial and sporadic primary pulmonary hypertension","volume":"23","author":"Morisaki","year":"2004","journal-title":"Hum Mutat"},{"issue":"11","key":"10.1016\/j.ijcchd.2025.100571_bib9","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1093\/cvr\/cvaa350","article-title":"Approaches to treat pulmonary arterial hypertension by targeting BMPR2: from cell membrane to nucleus","volume":"117","author":"Dunmore","year":"2021","journal-title":"Cardiovasc Res"},{"issue":"543","key":"10.1016\/j.ijcchd.2025.100571_bib10","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz5660","article-title":"ACTRIIA-Fc rebalances activin\/GDF versus BMP signaling in pulmonary hypertension","volume":"12","author":"Yung","year":"2020","journal-title":"Sci Transl Med"},{"issue":"13","key":"10.1016\/j.ijcchd.2025.100571_bib11","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1056\/NEJMoa2024277","article-title":"Sotatercept for the treatment of pulmonary arterial hypertension","volume":"384","author":"Humbert","year":"2021","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ijcchd.2025.100571_bib12","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01347-2022","article-title":"Sotatercept for the treatment of pulmonary arterial hypertension: PULSAR open-label extension","volume":"61","author":"Humbert","year":"2023","journal-title":"Eur Respir J"},{"issue":"5","key":"10.1016\/j.ijcchd.2025.100571_bib13","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCHEARTFAILURE.123.011227","article-title":"SPECTRA phase 2b study: impact of sotatercept on exercise tolerance and right ventricular function in pulmonary arterial hypertension","volume":"17","author":"Waxman","year":"2024","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.ijcchd.2025.100571_bib14","series-title":"Effect of sotatercept on central cardiopulmonary performance and peripheral oxygen transport during exercise in pulmonary arterial hypertension","author":"Reddy","year":"2024"},{"issue":"16","key":"10.1016\/j.ijcchd.2025.100571_bib15","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1056\/NEJMoa2213558","article-title":"Phase 3 trial of sotatercept for treatment of pulmonary arterial hypertension","volume":"388","author":"Hoeper","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijcchd.2025.100571_bib16","year":"2024"},{"key":"10.1016\/j.ijcchd.2025.100571_bib18","year":"2024"},{"key":"10.1016\/j.ijcchd.2025.100571_bib25","unstructured":"Study Details | A Study to Investigate the Safety and Efficacy of KER-012 in Combination With Background Therapy in Adult Participants With Pulmonary Arterial Hypertension (PAH) (TROPOS Study). | ClinicalTrials.gov. Accessed September 13, 2024. https:\/\/clinicaltrials.gov\/study\/NCT05975905?cond=Pulmonary%20Arterial%20Hypertension&term=ker-012&rank=1."},{"issue":"3","key":"10.1016\/j.ijcchd.2025.100571_bib26","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01609-2018","article-title":"Germline BMP9 mutation causes idiopathic pulmonary arterial hypertension","volume":"53","author":"Wang","year":"2019","journal-title":"Eur Respir J"},{"issue":"7","key":"10.1016\/j.ijcchd.2025.100571_bib27","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1038\/nm.3877","article-title":"Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension","volume":"21","author":"Long","year":"2015","journal-title":"Nat Med"},{"issue":"6","key":"10.1016\/j.ijcchd.2025.100571_bib28","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1161\/CIRCRESAHA.118.313356","article-title":"Selective BMP-9 inhibition partially protects against experimental pulmonary hypertension","volume":"124","author":"Tu","year":"2019","journal-title":"Circ Res"},{"issue":"3","key":"10.1016\/j.ijcchd.2025.100571_bib29","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.mvr.2010.05.010","article-title":"Bone morphogenic protein-9 stimulates endothelin-1 release from human pulmonary microvascular endothelial cells: a potential mechanism for elevated ET-1 levels in pulmonary arterial hypertension","volume":"80","author":"Star","year":"2010","journal-title":"Microvasc Res"},{"issue":"11","key":"10.1016\/j.ijcchd.2025.100571_bib30","doi-asserted-by":"crossref","first-page":"C1139","DOI":"10.1152\/ajpcell.00168.2012","article-title":"Inhibition of apelin expression by BMP signaling in endothelial cells","volume":"303","author":"Poirier","year":"2012","journal-title":"Am J Physiol Cell Physiol"},{"issue":"8","key":"10.1016\/j.ijcchd.2025.100571_bib32","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1080\/15548627.2018.1474314","article-title":"Chloroquine inhibits autophagic flux by decreasing autophagosome-lysosome fusion","volume":"14","author":"Mauthe","year":"2018","journal-title":"Autophagy"},{"issue":"48","key":"10.1016\/j.ijcchd.2025.100571_bib33","doi-asserted-by":"crossref","first-page":"37641","DOI":"10.1074\/jbc.M110.132415","article-title":"Identification of a lysosomal pathway regulating degradation of the bone morphogenetic protein receptor type II","volume":"285","author":"Durrington","year":"2010","journal-title":"J Biol Chem"},{"issue":"8","key":"10.1016\/j.ijcchd.2025.100571_bib34","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1161\/CIRCRESAHA.111.300483","article-title":"Chloroquine prevents progression of experimental pulmonary hypertension via inhibition of autophagy and lysosomal bone morphogenetic protein type II receptor degradation","volume":"112","author":"Long","year":"2013","journal-title":"Circ Res"},{"issue":"20","key":"10.1016\/j.ijcchd.2025.100571_bib35","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1093\/hmg\/ddn214","article-title":"Failure of bone morphogenetic protein receptor trafficking in pulmonary arterial hypertension: potential for rescue","volume":"17","author":"Sobolewski","year":"2008","journal-title":"Hum Mol Genet"},{"issue":"2","key":"10.1016\/j.ijcchd.2025.100571_bib36","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1165\/rcmb.2019-0321OC","article-title":"4PBA restores signaling of a cysteine-substituted mutant BMPR2 receptor found in patients with pulmonary arterial hypertension","volume":"63","author":"Dunmore","year":"2020","journal-title":"Am J Respir Cell Mol Biol"},{"key":"10.1016\/j.ijcchd.2025.100571_bib37","article-title":"StratosPHere: optimal biomarkers to ascertain target engagement in therapies targeting the BMPR2 pathway in pulmonary arterial hypertension (PAH)","year":"2023","journal-title":"clinicaltrials.gov"},{"key":"10.1016\/j.ijcchd.2025.100571_bib38","series-title":"Tolerability of LTP001 in participants with pulmonary arterial hypertension","article-title":"A randomized, participant- and investigator-blinded, placebo-controlled study to investigate efficacy, safety","year":"2024"},{"issue":"19","key":"10.1016\/j.ijcchd.2025.100571_bib39","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1161\/CIRCULATIONAHA.110.956839","article-title":"Epigenetic modifications: basic mechanisms and role in cardiovascular disease","volume":"123","author":"Handy","year":"2011","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.ijcchd.2025.100571_bib40","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1161\/CIRCULATIONAHA.113.006167","article-title":"Role for DNA damage signaling in pulmonary arterial hypertension","volume":"129","author":"Meloche","year":"2014","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ijcchd.2025.100571_bib41","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1084\/jem.20101812","article-title":"Role for miR-204 in human pulmonary arterial hypertension","volume":"208","author":"Courboulin","year":"2011","journal-title":"J Exp Med"},{"issue":"6","key":"10.1016\/j.ijcchd.2025.100571_bib42","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1161\/CIRCRESAHA.115.307004","article-title":"Bromodomain-containing protein 4: the epigenetic origin of pulmonary arterial hypertension","volume":"117","author":"Meloche","year":"2015","journal-title":"Circ Res"},{"key":"10.1016\/j.ijcchd.2025.100571_bib44","series-title":"Olaparib for pulmonary arterial hypertension: a multicenter clinical trial","author":"Provencher","year":"2023"},{"issue":"11","key":"10.1016\/j.ijcchd.2025.100571_bib45","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1164\/rccm.202109-2182LE","article-title":"BET protein inhibition for pulmonary arterial hypertension: a pilot clinical trial","volume":"205","author":"Provencher","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.ijcchd.2025.100571_bib46","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1164\/rccm.200707-1037OC","article-title":"Platelet-derived growth factor expression and function in idiopathic pulmonary arterial hypertension","volume":"178","author":"Perros","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"10","key":"10.1016\/j.ijcchd.2025.100571_bib47","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1161\/CIRCULATIONAHA.112.000765","article-title":"Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study","volume":"127","author":"Hoeper","year":"2013","journal-title":"Circulation"},{"issue":"4","key":"10.1016\/j.ijcchd.2025.100571_bib48","doi-asserted-by":"crossref","DOI":"10.1177\/20458940211052823","article-title":"Positioning imatinib for pulmonary arterial hypertension: a phase I\/II design comprising dose finding and single-arm efficacy","volume":"11","author":"Wilkins","year":"2021","journal-title":"Pulm Circ"},{"issue":"6","key":"10.1016\/j.ijcchd.2025.100571_bib49","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02356-2021","article-title":"Inhaled seralutinib exhibits potent efficacy in models of pulmonary arterial hypertension","volume":"60","author":"Galkin","year":"2022","journal-title":"Eur Respir J"},{"issue":"4","key":"10.1016\/j.ijcchd.2025.100571_bib50","doi-asserted-by":"crossref","DOI":"10.1177\/20458940211057071","article-title":"TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension","volume":"11","author":"Frantz","year":"2021","journal-title":"Pulm Circ"},{"key":"10.1016\/j.ijcchd.2025.100571_bib51","series-title":"A14. Building lego(LAND): LESSONS LEARNED from large scale clinical trials in PAH. American thoracic society International Conference Abstracts","article-title":"Interim results from the phase 1B and phase 2 TORREY open-label extension study of seralutinib in pulmonary arterial hypertension (PAH)","author":"Sitbon","year":"2024"},{"key":"10.1016\/j.ijcchd.2025.100571_bib52","series-title":"GB002, Inc. A phase 3, randomized, double-blind, placebo-controlled Study to Evaluate the Efficacy and Safety of oral Inhalation of Seralutinib for the Treatment of pulmonary arterial hypertension (PAH)","year":"2024"},{"issue":"9","key":"10.1016\/j.ijcchd.2025.100571_bib53","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1161\/CIRCULATIONAHA.109.933762","article-title":"Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension","volume":"122","author":"Soon","year":"2010","journal-title":"Circulation"},{"issue":"3","key":"10.1016\/j.ijcchd.2025.100571_bib54","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02463-2020","article-title":"Mendelian randomisation and experimental medicine approaches to interleukin-6 as a drug target in pulmonary arterial hypertension","volume":"59","author":"Toshner","year":"2022","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.ijcchd.2025.100571_bib55","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.12251","article-title":"SATISFY-JP, a phase II multicenter open-label study on Satralizumab, an anti-IL-6 receptor antibody, use for the treatment of pulmonary arterial hypertension in patients with an immune-responsive-phenotype: study protocol","volume":"13","author":"Tamura","year":"2023","journal-title":"Pulm Circ"},{"key":"10.1016\/j.ijcchd.2025.100571_bib56","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.954007","article-title":"Soluble markers of B cell activation suggest a role of B cells in the pathogenesis of systemic sclerosis-associated pulmonary arterial hypertension","volume":"13","author":"Sanges","year":"2022","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.ijcchd.2025.100571_bib57","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1164\/rccm.202009-3481OC","article-title":"Safety and efficacy of B-cell depletion with Rituximab for the treatment of systemic sclerosis-associated pulmonary arterial hypertension: a multicenter, double-blind, randomized, placebo-controlled trial","volume":"204","author":"Zamanian","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.ijcchd.2025.100571_bib58","series-title":"Efficacy and mechanism of anti-CD20 antibodies in systemic lupus erythematosus associated pulmonary arterial hypertension based on multi omics studies","year":"2024"},{"issue":"8","key":"10.1016\/j.ijcchd.2025.100571_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0183557","article-title":"Therapeutic benefits of intravenous cardiosphere-derived cell therapy in rats with pulmonary hypertension","volume":"12","author":"Middleton","year":"2017","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.ijcchd.2025.100571_bib60","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.stemcr.2014.04.006","article-title":"Exosomes as critical agents of cardiac regeneration triggered by cell therapy","volume":"2","author":"Ibrahim","year":"2014","journal-title":"Stem Cell Rep"},{"key":"10.1016\/j.ijcchd.2025.100571_bib61","article-title":"The ALPHA phase 1 study: pulmonary ArteriaL hypertension treated with CardiosPHere-Derived allogeneic stem cells","volume":"100","author":"Lewis","year":"2023","journal-title":"EBioMedicine"},{"issue":"3","key":"10.1016\/j.ijcchd.2025.100571_bib62","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1002\/(SICI)1097-4652(199603)166:3<495::AID-JCP4>3.0.CO;2-K","article-title":"Exogenous leukocyte and endogenous elastases can mediate mitogenic activity in pulmonary artery smooth muscle cells by release of extracellular-matrix bound basic fibroblast growth factor","volume":"166","author":"Thompson","year":"1996","journal-title":"J Cell Physiol"},{"issue":"4","key":"10.1016\/j.ijcchd.2025.100571_bib63","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1016\/j.chest.2021.06.028","article-title":"Severe pulmonary arterial hypertension is characterized by increased neutrophil elastase and relative elafin deficiency","volume":"160","author":"Sweatt","year":"2021","journal-title":"Chest"},{"key":"10.1016\/j.ijcchd.2025.100571_bib64","series-title":"Safety and tolerability of escalating doses of subcutaneous elafin (Tiprelestat) injection in healthy normal subjects","author":"Zamanian","year":"2024"},{"key":"10.1016\/j.ijcchd.2025.100571_bib65","series-title":"Tolerability and pharmacokinetics of intravenous ZMA001 in healthy subjects","article-title":"A phase 1 randomized, double-blind, placebo-controlled, single-ascending dose study to evaluate the safety","year":"2024"},{"issue":"3","key":"10.1016\/j.ijcchd.2025.100571_bib31","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02449-2016","article-title":"Randomised placebo-controlled safety and tolerability trial of FK506 (tacrolimus) for pulmonary arterial hypertension","volume":"50","author":"Spiekerkoetter","year":"2017","journal-title":"Eur Respir J"},{"issue":"15","key":"10.1016\/j.ijcchd.2025.100571_bib66","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1161\/CIRCULATIONAHA.105.591321","article-title":"Cross talk between endothelial and smooth muscle cells in pulmonary hypertension","volume":"113","author":"Eddahibi","year":"2006","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.ijcchd.2025.100571_bib67","doi-asserted-by":"crossref","DOI":"10.1002\/pul2.12088","article-title":"A trial design to maximize knowledge of the effects of rodatristat ethyl in the treatment of pulmonary arterial hypertension (ELEVATE 2)","volume":"12","author":"Lazarus","year":"2022","journal-title":"Pulm Circ"},{"issue":"11","key":"10.1016\/j.ijcchd.2025.100571_bib68","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/S2213-2600(24)00226-1","article-title":"Safety and efficacy of rodatristat ethyl for the treatment of pulmonary arterial hypertension (ELEVATE-2): a dose-ranging, randomised, multicentre, phase 2b trial","volume":"12","author":"Sitbon","year":"2024","journal-title":"Lancet Respir Med"},{"issue":"38","key":"10.1016\/j.ijcchd.2025.100571_bib69","doi-asserted-by":"crossref","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","article-title":"ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension","volume":"43","author":"Humbert","year":"2022","journal-title":"Eur Heart J"},{"issue":"5","key":"10.1016\/j.ijcchd.2025.100571_bib70","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1038\/sj.bjp.0704778","article-title":"NO- and haem-independent activation of soluble guanylyl cyclase: molecular basis and cardiovascular implications of a new pharmacological principle","volume":"136","author":"Stasch","year":"2002","journal-title":"Br J Pharmacol"},{"issue":"1","key":"10.1016\/j.ijcchd.2025.100571_bib71","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1186\/s12931-022-02189-1","article-title":"Inhaled mosliciguat (BAY 1237592): targeting pulmonary vasculature via activating apo-sGC","volume":"23","author":"Becker-Pelster","year":"2022","journal-title":"Respir Res"},{"issue":"4","key":"10.1016\/j.ijcchd.2025.100571_bib72","first-page":"382","article-title":"Role of prostacyclin in pulmonary hypertension","volume":"2014","author":"Mitchell","year":"2014","journal-title":"Global Cardiol Sci. Pract."},{"issue":"4","key":"10.1016\/j.ijcchd.2025.100571_bib73","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01030-2019","article-title":"Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial","volume":"54","author":"Torres","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijcchd.2025.100571_bib74","author":"Therapeutics"}],"container-title":["International Journal of Cardiology Congenital Heart Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666668525000072?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666668525000072?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T07:46:30Z","timestamp":1741851990000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666668525000072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":66,"alternative-id":["S2666668525000072"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcchd.2025.100571","relation":{},"ISSN":["2666-6685"],"issn-type":[{"value":"2666-6685","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New therapies in pulmonary arterial hypertension: Recent insights","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology Congenital Heart Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcchd.2025.100571","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100571"}}